(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
5 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 10.63%
Live Chart Being Loaded With Signals
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease...
Stats | |
---|---|
今日成交量 | 41 004.00 |
平均成交量 | 346 216 |
市值 | 80.71M |
EPS | $0 ( 2024-03-04 ) |
下一个收益日期 | ( $-0.370 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.700 |
ATR14 | $0.0120 (0.92%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Borthwick Kathleen | Buy | 227 000 | Employee Stock Option (right to buy) |
2024-03-15 | Forman Mark S | Buy | 203 000 | Employee Stock Option (right to buy) |
2024-03-15 | Chou William | Buy | 575 000 | Employee Stock Option (right to buy) |
2024-03-15 | Cale Edgar B. | Buy | 203 000 | Employee Stock Option (right to buy) |
2024-02-10 | Borthwick Kathleen | Buy | 4 000 | Common Stock |
INSIDER POWER |
---|
82.09 |
Last 96 transactions |
Buy: 8 238 559 | Sell: 441 732 |
音量 相关性
Passage Bio Inc 相关性 - 货币/商品
Passage Bio Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-3.72M (0.00 %) |
EPS: | $-1.860 |
FY | 2023 |
营收: | $0 |
毛利润: | $-3.72M (0.00 %) |
EPS: | $-1.860 |
FY | 2022 |
营收: | $0 |
毛利润: | $-3.68M (0.00 %) |
EPS: | $-2.51 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.48 |
Financial Reports:
No articles found.
Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。